Veru Inc. (NASDAQ: VERU), a late clinical stage biopharmaceutical company focused on developing innovative medicines for ...

Veru (NASDAQ:VERU – Get Free Report) is expected to be releasing its earnings data before the market opens on Thursday, February 6th. Analysts expect Veru to post earnings of ($0.08) per share and ...

In another example of the volatility facing developers of obesity drugs, Veru saw its share price cut nearly in half – despite reporting ostensibly positive data for a drug candidate.

Latest data shows the largest indicative borrow rate increases among liquid option names include: Veru (VERU) 2.09% +0.85, NovaDel Pharma ...

HR+/HER2- breast cancer is the most prevalent subtype of breast cancer, defined by cancer cells that possess hormone ...

Enobosarm demonstrated a statistically significant benefit in preserving lean mass in patients with overweight or obesity undergoing treatment with semaglutide.Topline results from the Phase ...

Veruschka Foundation trains people with developmental disabilities in culinary and essential life skills that will help them ...

Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings ...

A global pharmaceutical company partnered with DelveInsight to create a robust and simplified solution enabling its top executives to monitor the evolving breast cancer competitive intelligence ...

Pre-Market: 9:25:12 a.m. EST ...

Curently the only available blood test to tell which women are at risk of postpartum depression (PPD) is the one that ...

Japan’s drug pricing scheme has gotten more complicated, and pharma companies should brace themselves for annual price cuts.